Pexelizumab,an anti-C5 complement antibody,as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial |
| |
| Authors: | Granger Christopher B,Mahaffey Kenneth W,Weaver W Douglas,Theroux Pierre,Hochman Judith S,Filloon Thomas G,Rollins Scott,Todaro Thomas G,Nicolau Jose C,Ruzyllo Witold,Armstrong Paul W COMMA Investigators |
| |
| Affiliation: | Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA. grang001@mc.duke.edu |
| |
| Abstract: | |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
